203 related articles for article (PubMed ID: 11555679)
1. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses.
Simonaro CM; Haskins ME; Schuchman EH
Lab Invest; 2001 Sep; 81(9):1319-28. PubMed ID: 11555679
[TBL] [Abstract][Full Text] [Related]
2. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models.
Simonaro CM; D'Angelo M; Haskins ME; Schuchman EH
Pediatr Res; 2005 May; 57(5 Pt 1):701-7. PubMed ID: 15746260
[TBL] [Abstract][Full Text] [Related]
3. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M
PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI.
Eliyahu E; Wolfson T; Ge Y; Jepsen KJ; Schuchman EH; Simonaro CM
PLoS One; 2011; 6(8):e22447. PubMed ID: 21887218
[TBL] [Abstract][Full Text] [Related]
5. Structural, compositional, and biomechanical alterations of the lumbar spine in rats with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).
Lai A; Simonaro CM; Schuchman EH; Ge Y; Laudier DM; Iatridis JC
J Orthop Res; 2013 Apr; 31(4):621-31. PubMed ID: 23192728
[TBL] [Abstract][Full Text] [Related]
6. Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.
Crawley AC; Yogalingam G; Muller VJ; Hopwood JJ
J Clin Invest; 1998 Jan; 101(1):109-19. PubMed ID: 9421472
[TBL] [Abstract][Full Text] [Related]
7. Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.
Auclair D; Hein LK; Hopwood JJ; Byers S
Pediatr Res; 2006 Apr; 59(4 Pt 1):538-43. PubMed ID: 16549525
[TBL] [Abstract][Full Text] [Related]
8. Growth plate pathology in feline mucopolysaccharidosis VI.
Abreu S; Hayden J; Berthold P; Shapiro IM; Decker S; Patterson D; Haskins M
Calcif Tissue Int; 1995 Sep; 57(3):185-90. PubMed ID: 8574934
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of clinical features and arylsulfatase B gene mutation in thirteen Chinese children with mucopolysaccharidosis type VI].
Zheng J; Huang Y; Zhao X; Sheng H; Cheng J; Zhou Z; Li X; Mao X; Liu L
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):403-8. PubMed ID: 25190157
[TBL] [Abstract][Full Text] [Related]
10. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.
Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A
Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699
[TBL] [Abstract][Full Text] [Related]
11. Arylsulfatase B activities and glycosaminoglycan levels in retrovirally transduced mucopolysaccharidosis type VI cells. Prospects for gene therapy.
Fillat C; Simonaro CM; Yeyati PL; Abkowitz JL; Haskins ME; Schuchman EH
J Clin Invest; 1996 Jul; 98(2):497-502. PubMed ID: 8755662
[TBL] [Abstract][Full Text] [Related]
12. Mucopolysaccharidosis VI.
Valayannopoulos V; Nicely H; Harmatz P; Turbeville S
Orphanet J Rare Dis; 2010 Apr; 5():5. PubMed ID: 20385007
[TBL] [Abstract][Full Text] [Related]
13. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
[TBL] [Abstract][Full Text] [Related]
14. Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).
Saccone P; Cotugno G; Russo F; Mastrogiacomo R; Tessitore A; Auricchio A; De Leonibus E
Sci Rep; 2014 Jan; 4():3644. PubMed ID: 24407717
[TBL] [Abstract][Full Text] [Related]
15. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
16. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of multiple dentigerous cysts in a patient with the Maroteaux-Lamy syndrome (mucopolysaccharidosis, type VI).
Roberts MW; Barton NW; Constantopoulos G; Butler DP; Donahue AH
Oral Surg Oral Med Oral Pathol; 1984 Aug; 58(2):169-75. PubMed ID: 6435047
[TBL] [Abstract][Full Text] [Related]
19. Arylsulfatase B-deficient mucopolysaccharidosis in rats.
Yoshida M; Noguchi J; Ikadai H; Takahashi M; Nagase S
J Clin Invest; 1993 Mar; 91(3):1099-104. PubMed ID: 8450039
[TBL] [Abstract][Full Text] [Related]
20. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses.
Schuchman EH; Ge Y; Lai A; Borisov Y; Faillace M; Eliyahu E; He X; Iatridis J; Vlassara H; Striker G; Simonaro CM
PLoS One; 2013; 8(1):e54459. PubMed ID: 23365668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
